Pfizer CEO: new Guankou medicine is expected to be listed at the end of this year

Pfizer’s experimental oral neocrown treatment is expected to be available by the end of this year, CEO Albert bourla said on Tuesday

.

The company started an early clinical trial in March to test a new antiviral therapy

.

The drug is an effective protease inhibitor against the activity of new coronavirus

.

Protease inhibitors can prevent virus replication in cells

.

These drugs have been proved to be effective against pathogens of other viruses, such as HIV and HCV, when used alone or in combination with other antiviral drugs

.

Mikael dolsten, Pfizer’s chief scientific officer and President of global research and development, said earlier that the drug was designed as an oral drug focusing on mild diseases and could be prescribed when novel coronavirus infections appeared

.

Bourla said the drug could be on the market in the United States by the end of this year if clinical trials proceed smoothly and it is approved by the food and drug administration

.

Health experts say the oral treatment may “change the rules of the game” because people newly infected with the new coronavirus can use it outside the hospital

.

The researchers hope the drug will prevent further development of the disease and prevent hospitalization

.

In addition to the drug, Pfizer is testing its novel coronavirus vaccine for children between six months and 11 years old

.

Public health officials and infectious disease experts say vaccinating children is crucial to ending the epidemic

.

Earlier this month, Pfizer asked the FDA to extend its vaccine authorization to 12 to 15 year olds

.

Bourla said on Tuesday that he was “very optimistic.”

.

Statement: the research contents are all from the Internet, not responsible for the 100% authenticity of the research contents, only responsible for the transportation of the research contents

.

It’s not a stock recommendation, it’s just a record of personal investment speculation..

.